Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7807797 | 1.00 | HDAC6 (0.71) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL7801066 | 0.99 | HDAC6 (0.70) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL8588244 | 0.99 | HDAC6 (0.70) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL8588240 | 0.99 | HDAC6 (0.70) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL7801064 | 0.99 | HDAC6 (0.70) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL7812627 | 0.99 | HDAC6 (0.70) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL7812631 | 0.99 | HDAC6 (0.70) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL7801036 | 0.98 | HDAC6 (0.71) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL7801038 | 0.98 | HDAC6 (0.71) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL7639766 | 0.96 | HDAC6 (0.70) | HDAC6ADORA2AADORA2BSLC29A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6307043-B1 | FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS | GLAXO WELLCOME INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010003744-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY DAWES (US) | 2001-06-14 | — | — | US | disclosed |
| US-6077832-A | FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION | GLAXO WELLCOME INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0769017-B1 | THERAPEUTIC COMPOUNDS | WELLCOME FOUND (GB) | 2000-05-24 | — | — | EP | disclosed |
| US-5998605-A | Antiviral benzimidazole nucleoside analogues and method for their preparation | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1996001833-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003744-A1 | Therapeutic compounds | ZC3HAV1, HAVCR2, EIF2AK2 | HDAC6 78/4885ADORA2A 1710/4885ADORA2B 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.